Showing 51-60 of 327 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Tolerance inducing NanoLymph for in vivo generation of islet autoantigen-specific regulatory T cells | The Methodist Hospital Research Institute | Ying Xuan Chua | Cures | 01-April-2025 to 31-March-2026 | $200.000,00 |
| Cardiotoxic Circulating Extracellular Vesicles: New Drivers of Type 1 Diabetes-induced Cardiomyopathy | Icahn School of Medicine at Mount Sinai | Susmita Sahoo | Improving Lives | 01-April-2025 to 31-March-2026 | $199.998,24 |
| The role of iron metabolism in T cell subsets in type 1 diabetes | Rector & Visitors of the University of Virginia | Kelsey Voss | Cures | 01-March-2025 to 28-February-2026 | $110.000,00 |
| Curing New-Onset Type 1 Diabetes with a Restorative Antibody Therapy | Johns Hopkins University | Dax Fu | Cures | 01-April-2025 to 31-March-2026 | $200.000,00 |
| Novel mechanisms of ketoacidosis with SGLT2 inhibitors in type 1 diabetes | Regents of the University of Michigan | Jennifer Schaub | Improving Lives | 01-April-2025 to 31-March-2026 | $200.000,00 |
| Engineering a novel Treg population to control autoimmune diabetes | University of Kansas Medical Center Research Institute, Inc. | Mary Markiewicz | Cures | 01-April-2025 to 31-March-2026 | $199.999,62 |
| A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation | The University of Chicago | Piotr Witkowski | Cures | 01-February-2025 to 31-January-2027 | $1.000.000,00 |
| Advancing T1D Detection and Care Through AI | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-February-2025 to 31-January-2026 | $345.083,00 |
| Targeting self-RNA sensing as a trigger of inflammation in type 1 diabetes | Trustees of the University of Pennsylvania | Qin Li | Cures | 01-April-2025 to 31-March-2026 | $199.919,54 |
| Protective Genetic and Pharmacological Interventions to Prevent Cytokine and Autoimmune-based Destruction of β cells. | Icahn School of Medicine at Mount Sinai | Romina Bevacqua | Cures | 01-April-2025 to 31-March-2027 | $559.996,54 |